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Abstract
Background: Addiction constitutes a major public health problem, and despite treatment, relapse rates remain very
high. Preliminary findings suggest that Eye Movement Desensitization and Reprocessing (EMDR), an evidence-based
treatment for PTSD, may also reduce craving and relapse rates when applied in substance abuse. This study aims to
determine the feasibility, efficacy and effectiveness of EMDR when added to treatment as usual (TAU) for addiction
in alcohol dependent outpatients, compared to TAU only.
Methods/Design: A single blinded study in which 100 adult patients with a primary DSM-IV-TR diagnosis of alcohol
dependence or abuse receiving treatment in one of six Dutch outpatient addiction care facility sites, will be enrolled.
After baseline assessment participants will be allocated to one of two treatment conditions (allocation ratio of 1:1) using
a stratified (per site, per care pathway), blocked randomization procedure. The intervention consists of EMDR (seven
weekly 90 minute sessions) + TAU or TAU only. Assessments are scheduled pre-treatment (t0), post-treatment (t0 + eight
weeks), and one and six months post treatment. The effects of both treatment arms are compared on indices of (a)
drinking behavior, (b) mediators, moderators and predictors of treatment outcome, (c) quality of life and d) safety,
acceptability and feasibility of treatment.
Repeated measures ANOVA’s will be conducted using an intention-to-treat and per-protocol approach. Multiple
imputation will be used to deal with missing values when possible.
Discussion: This study adapts and extends the standard EMDR treatment for traumatized patients for use with patients
with alcohol use disorders without psychological trauma.
Trial registration: ClinicalTrial.gov: NCT01828866
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Background
In 2013 in the Netherlands, 46% of all treatment seeking
patients with an addiction problem (more than 65.000)
sought help for alcohol-related problems [1]. However,
despite treatment, addictions such as alcohol dependence
are characterized by high relapse rates [2]. For 1-year out-
comes across alcohol, nicotine, and illicit drug abuse, more
than 85% of patients relapse within 1 year of treatment.
Many factors are implicated in the genesis, escalation
and maintenance of addiction. Here some known predic-
tors of alcohol use are discussed before we introduce a
relatively new approach to target some of these mecha-
nisms in order to reduce drinking behavior. A multi-
factorial approach is adopted to gain insight into possible
mechanisms of change regarding this approach.
Mediators, moderators and predictors of alcohol use
and relapse
Addiction can be conceptualized as a cyclic process of
anticipation, intoxication, and withdrawal [3]. The an-
ticipation stage is considered a key element of relapse
and often takes the form of intense craving. Craving re-
fers to a compelling or intense urge, desire or intention
to ingest a drug [4]. High baseline levels of alcohol crav-
ing may define a subtype of alcohol dependence that is
less responsive to treatment and predict the chance of
relapse after discharge [5]. In addition to craving itself it
may be interesting to look at related concepts, such as
desire thinking and rumination, which seem to augment
craving.
Desire thinking refers to the elaboration of cognitions
and imagery in working memory which may escalate
craving intensity [6]. It correlates with escalating levels
of drinking status [7]. Desire thinking is regarded as a
specific type of perseverative thinking, such as rumin-
ation or worry [6]. Interestingly, rumination predicts
long term outcomes of addiction treatment in alcohol-
dependent patients [8]. Rumination increases craving in
alcohol-dependent drinkers but not in problem and social
drinkers [9]. So both desire thinking and rumination in-
crease or intensify craving. Since rumination results in in-
creased negative affect [10], it is no surprise that both low
positive and high negative affect are associated with relapse
in addiction [11]. So when levels of desire thinking and ru-
mination are reduced, craving and negative affect may also
be reduced, which would result in lower relapse rates.
In addition to these subjective processes, automatic
implicit processes such as attentional biases have also
been implicated in the maintenance of addiction [12,13].
Since alcohol attentional biases have a reciprocal excita-
tory relationship with craving, reductions in attentional
bias should predict reductions in craving and drinking
behavior. Whereas craving, desire thinking, rumination
and negative affect are typically measured by subjective
participant report, the strength of implicit processes may
be measured more objectively in paradigms using changes
in reaction times as primary outcome.
Other known predictors of alcohol treatment outcome
which will be assessed in this study are baseline alcohol
consumption, dependence severity, employment, gender,
psychopathology rating, treatment history, motivation,
socioeconomic status/income and self-efficacy [14]. In-
creased self-efficacy during treatment predicts a positive
treatment outcome while an excess of self-efficacy can
be inconsistent with the actual ability of a patient to re-
sist use and may result in drop-out.
In sum, there is a large body of research on predictors
of alcohol treatment outcome. These factors should be
taken into account when aiming to reduce relapse rates
since they can help identify at an early stage which inter-
ventions may have the highest clinical effectiveness over
time. In addition, they provide important targets for dir-
ect intervention.
In this study we focus on an approach which targets epi-
sodic drug memories to reduce craving, alcohol consump-
tion and relapse rates: Eye Movement Desensitization and
Reprocessing (EMDR) [15].
Research on EMDR in addiction
EMDR is a structured treatment for posttraumatic stress
disorder (PTSD) [16]. The core of the procedure entails
the identification and reactivation of specific memory
representations in working memory while the patient
follows the therapist’s horizontal hand movements with
her or his eyes. Since this taxes working memory and
working memory is limited in capacity, the eye move-
ments compete for attention with the reactivated memory
[17]. Every 30 seconds, the patient reports spontaneous as-
sociations, which form the focus of attention during a new
set of eye movements. Over time the memory representa-
tion gets less vivid and emotionally charged (‘desensiti-
sized’) while a new, more adaptive self-perspective tends
to arise [18]. The EMDR procedure can also be used to
desensitize dysfunctional positive memory representations
[19] or that of anticipated events [20].
Research has clearly demonstrated EMDR’s effect in the
treatment of PTSD [21]. Some have suggested that, on the
basis of an emerging body of research, EMDR may be
regarded as a general model for psychotherapy for a wider
range of conditions, such as addiction [22]. However, re-
search on the efficacy and effectiveness of EMDR on ad-
diction is still limited, consisting mostly of anecdotal
reports or case studies of substance-related [23-31] as well
as behavioral addictions [32-37]. Although most of these
reports and case studies found positive results, some
found mixed [30] or negative results [24,25]. The inter-
pretation of results is further complicated by the fact that
different approaches were used [36,38,39].
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To date, one RCT has been published [15]. Detoxified,
in-patient alcohol dependent patients received TAU plus
two one-hour sessions of EMDR targeting memory repre-
sentations of intense craving or relapse. Controls received
TAU only. Decreased craving at 1-month follow-up, as
well as a lower relapse rate at 1- and 6-month follow-up
were found in the experimental group. However, the sam-
ple size was small (n = 34), attrition was high, assessment
depended fully on self-report and treatment was applied
by the researcher. This raises questions about the actual
efficacy and effectiveness of EMDR. In addition, although
no adverse effects were reported, this study showed that
relapse or study drop-out rates may still be substantial and
should be taken into account when determining the feasi-
bility of the treatment.
In sum, although limited data and methodological is-
sues prohibit firm conclusions, further research on the
efficacy of EMDR in addiction is warranted.
Objectives
Primary objective – effects of treatment on drinking behavior
This study examines the efficacy and effectiveness of
EMDR + TAU versus TAU only on drinking behaviour in
a sample of alcohol dependent participants.
We operationalize drinking behavior as: a) changes in
number of heavy drinking days (days on which ≥ 5 stand-
ard drinks of alcohol are consumed); b) time to first alco-
hol drink (only relevant if abstinence was reached before
the previous assessment); c) changes in total drinks con-
sumed in the past 30 days; and d) changes in average
drinks per occasion in the past 30 days (total drinks di-
vided by drinking days). Participant-reported informa-
tion is backed-up with changes in relevant biomarker
data (derived from blood samples at all time-points):
carbohydrate-deficient transferrin (CDT) combined with
serum γ-glutamyltransferase (GGT). An overview of the
measurements at different time points is given in Table 1.
The primary outcome variable is changes in number
of heavy drinking days since escalating numbers of heavy
drinking days may best reflect a (temporarily) loss of
control of drinking behavior, while the other behavioral
outcomes could also reflect (to some degree) social or
controlled drinking behavior.
Secondary objectives – mediators, moderators and
predictors of treatment outcome
To explore mechanisms of change, variables that are po-
tential predictors, mediators or moderators of treatment
outcome will be examined (see Table 1). We distinguish:
1. Dependent variables:
a. Psychological (participant report): desire thinking,
craving, rumination, negative affect and coping
self-efficacy,
b. Psychological (reaction times): alcohol
attentional bias and implicit associations
towards alcohol cues.
2. Covariates:
a. Measured at baseline: demographic
characteristics, time-in-treatment, comorbid
psychopathology, alcohol consumption, alcohol
dependence severity, other substance use and
readiness to change;
b. Measured between baseline and follow-up:
completer status, time-in-treatment, treatment
intensity, the use of psychopharmaca, anticraving
(naltrexone and acamprosate) or alcohol
abstinence enforcing medication (disulfuram).
Tertiary objective – effects of treatment on quality of life
The aim of addiction treatment is recovery which can
be defined as abstinence plus improved quality of life
[40]. Therefore, quality of life will be assessed in
addition to the drinking related variables mentioned
above (see Table 1).
Quarteniary objectives – safety, acceptability and feasibility
of treatment
Expectancies and experiences about treatment of both
participants and therapists may affect treatment outcome.
Therefore harm expectancy and experience, expected and
experienced burden, credibility of treatment and treatment
adherence will be assessed.
Methods/design
Design
This study is a randomized controlled trial with two arms:
EMDR+TAU versus TAU. The two groups are compared
pre-treatment (T0), post treatment (T1 =T0 + 8 weeks)
and at follow up one (T2) and six months (T3) post treat-
ment, on variables linked to the research questions. This
amounts to a 2 × 4 design with the between factor condi-
tion (EMDR+TAU vs. TAU) and within factor time (pre- x
post intervention × 1 × 6 months follow-up).
Both groups will be assessed at the same time-points,
whereby a substantial part of both groups may still re-
ceive TAU at follow-up after 1 month, but may no lon-
ger receive TAU at follow-up after 6 months.
The current study is hybrid in that it tries to broaden
the generalizability of the outcomes by recruiting a rep-
resentative, but complex sample while maintaining some
of the rigor of efficacy research (e.g. using training and
supervision, monitoring of and feedback on treatment fi-
delity). This allows to analyze data from an effectiveness
(outcome in real life circumstances, using all data, in-
cluding imputed data in case of study drop-out etc.) and
an efficacy (outcome under ideal circumstances using
only completers data) viewpoint.
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The design of this study was approved by the Medical
Ethics Committee of Medisch Spectrum Twente and is
registered as study NL43892.044.13.
Participants and recruitment
Adult patients, 18 years or older, with a primary DSM-
IV-TR [41] diagnosis of alcohol dependence or abuse are
recruited from six outpatient sites of IrisZorg, an addic-
tion treatment organization in the Netherlands. The trial
process starts with a global identification of possible eli-
gible patients (on the basis of known in- and exclusion
criteria, see next paragraph) by a triagist when they seek
treatment. If they agree to be informed about the study,
they are contacted by a research assistant (RA1, a psych-
ologist) to provide additional information and to answer
questions. Participants consent to postponed information
after they receive limited oral and written information to
be able to blind them as much as possible from later group
allocation using the procedure outlined by [42]. After con-
sent, an appointment is made for an inclusion interview. If
included, participants undergo a pre-treatment assessment
(T0) (see Figure 1).
Inclusion and exclusion
The inclusion criteria are:
1. Age 18 or older;
2. Fluent in Dutch speaking and reading abilities
(clinical observation by RA1) and;
3. A primary DSM-IV-TR diagnosis of alcohol
dependence or abuse.
This last criterion is assessed during the regular intake
procedure by a health care or clinical psychologist.
Exclusion criteria are:
1. Meeting the DSM-IV-TR criteria for current PTSD;
2. Meeting the DSM-IV-TR criteria for current
dependence and regular (at least once per week in
the last 2 weeks before eligibility screening) use of
substances other than alcohol or nicotine;
Table 1 Measurements of primary, secondary and tertiary objectives: drinking behavior, mediators, moderators and
predictors and quality of life
Outcome Measurement Baseline screening T0 T1 T2 T3
-interview (i) Pretreatment Posttreatment 1 month FU 6 months FU
-self-report (s)
-reaction time (r)
-bloodsample (b)
1 Recent and lifetime use, indications
for psychiatric or medical evaluation,
addiction treatment history and current
abuse or dependence (DSM-IV)
MATE (part 1–4) (i) X
2 Comorbid psychiatry (DSM-IV) MINI-plus (i) X
3 Motivation to change RCQ-D (s) X
4 Harmful alc. use AUDIT (30 d) (s) X X X X
5 Self-efficacy SELD (s) X X X X
6 Health outcome EQ-5D (s) X X X X
7 Quality of life CRA-HS (s) X X X X
8 Alcohol craving PACS (s) X X X X
9 Desire thinking DTQ (s) X X X X
10 Pos. and neg. affect PANAS-SF (s) X X X X
11 Rumination PTQ (s) X X X X
12 Drinking behavior TLFB (30 d) (i) X X X X
13 Alcohol attentional bias Alcohol Stroop (r) X X X X
14 Alcohol implicit assoc. Valence IAT (r) X X X X
15 Biomarkers chron. alc. use GGT + CDT (b) X X X X
AUDIT Alcohol Use Disorders Identification Test, CDT carbohydrate-deficient transferrin, CRA-HS Community Reinforcement Approach Happiness Scale, DSM-IV
Diagnostic and Statistical Manual – 4th ed., DTQ Desire Thinking Questionnaire, EQ-5D™ EuroQol - 5 dimensions, GGT serum γ-glutamyltransferase, IAT Implicit
Association Task, M.I.N.I.-plus M.I.N.I. International Neuropsychiatric Interview-Plus, PACS Penn Alcohol Craving Scale, PANAS-SF Positive And Negative Affect
Schedule – Short Form, PTQ Perseverative Thinking Questionnaire, RCQ-D Readiness to Change Questionnaire - Dutch version, SELD Self-Efficacy List for Drug
users, TLFB Timeline Followback.
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3. Current (in the last two weeks before eligibility
screening) regular alcohol use (at least > 21E
(women) or > 28E (men) per week) and;
4. Severe, current (since the start of regular treatment)
psychiatric symptoms (especially manic, psychotic,
suicidal and aggressive symptoms) that interfere
with TAU.
These criteria are assessed during intake by a health care
or clinical psychologist and/or (re)assessed by RA1 during
screening. RA1 uses segments of the Mini-International
Neuropsychiatric Interview-Plus (MINI-Plus [43]), the
Measurements in the Addictions for Triage and Evalu-
ation (MATE 2.1 [44]) and/or clinical observation as well
as information from the patients dossier.
When RA1 detects psychopathology not detected dur-
ing regular intake, the participant is informed as well as
his/her regular therapist to ensure further diagnostics
and treatment is provided, if necessary.
Randomization and allocation
After inclusion, participants are randomized to either
EMDR+TAU or “TAU only” by another RA (RA2, a
psychologist), not involved in the assessments. Participants
are allocated to their treatment condition based on a
randomization code. RA2 generates a randomization se-
quence before the recruitment phase starts using freely
available software [45].
The randomization sequence is stratified by participat-
ing facility (a total of six sites), further subdivided by a
maximum of three care pathway (‘youth’ (youngsters up
to 23 years old), ‘addiction’ (adult patients with primarily
addiction) or ‘addition, care and housing’ (adult patients
with problems on multiple life domains in addition to
addiction and often severe psychiatric problems), if there
is a participating EMDR therapist available in that stri-
atum. EMDR therapists may work at multiple facilities
and/or care pathways and thus see participants from dif-
ferent strata. This amounts to a stratified randomization
with a 1:1 group allocation within each stratum, using
block sizes of 4.
When participants are allocated to TAU only, no ac-
tion is taken (since RA1 already planned subsequent as-
sessments, independent of allocation). When they are
allocated to EMDR + TAU, RA2 informs participants by
email about EMDR with additional written information.
RA2 also informs a participating EMDR therapist of the
same facility where the participant receives TAU. The
EMDR therapist contacts the participant and provides
additional information about EMDR to the participant
and plans seven weekly EMDR sessions.
Great care is taken so that all those involved in the study
are blinded as much as possible. Participants, RA1 (the as-
sessor) and the principal investigator are blinded to group
allocation while EMDR therapists are blinded to outcome
of assessments. In addition, the principal investigator was
not involved in the treatment of participants.
Power and sample size calculation
Since two active treatment arms are compared and the
sample is expected to be relatively heterogeneous regard-
ing baseline variables such as dependence severity, drink-
ing status and other substance use, it is estimated that the
effect size will be relatively small. Clinical relevant differ-
ences on the primary outcome variable (changes in num-
ber of heavy drinking days in the previous 30 days) were
calculated on the basis of data of a recent study [46]. In
patients with an alcohol-use disorder referred to in- or
outpatient alcohol treatment the mean baseline score for
heavy drinking days (≥5 drinks in a single day, over the
past 30 days) was 16.33 (SD 11.99). Treatment outcome
was such that undertreated patients (<75% attendance of
the number of sessions recommended by treatment alloca-
tion guidelines, n = 618) showed a reduction of 8.7 heavy
drinking days (±12.5) while overtreated patients (>110%
attendance of sessions recommended) showed a reduction
of 12.5 heavy drinking days (±12.2, n = 362). The differ-
ence between under- and overtreated patients is at least
Enrollment
Follow-Up
Allocation
Identification of possible eligible patients with
alcohol dependence or abuse
Consent to postponed information
Inclusion Exclusion
T0
T3
T1
T2
Randomisation
EMDR + TAU TAU
T3
T1
T2
Maybe interested to participate Not interested
in participation
Inclusion interview
Figure 1 Flow Diagram RCT.
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3.8 heavy drinking days over the past 30 days which corre-
sponds to an effect size of d = 0.31 or f = 0.15).
Subsequent poweranalysis in G*Power version 3.1.2.
[47] (ANOVA: repeated measures, within-between inter-
action) indicated a sample size of 74 to demonstrate this
effect (keeping α at 0.05 and power at 0.80 and using 2
groups and 3 measurements (concerning changes in the
number of heavy drinking days between 4 time points)).
Attrition is estimated to be relatively high at 33%. There-
fore we add 26 participants (100 patients in total, 50 in
each treatment arm), to meet the required sample size.
To minimize missing values RA1 will use email, text
messages, telephone calls, and/or contacts with partici-
pants’ regular therapists to remind participants about
their assessment appointments. All participants will re-
ceive financial compensation of 25 euros (in the form of
a gift cheque) for every complete assessment at T2 and
T3, regardless of whether or not the participant drops
out of treatment.
Interventions
Treatment as usual (TAU)
All participants already receive TAU at the moment they
are enrolled and will continue to receive TAU for as long
as indicated by their regular therapists but at least until
T1. TAU may differ in intensity or additional compo-
nents delivered (e.g. family treatment) between partici-
pants. In IrisZorg, most out-patients of care pathway
‘youth’ and ‘addiction’ receive (Adolescent) Community
Reinforcement Approach ((A)CRA) treatment, consist-
ing of several interventions, based on behavioral therapy
principles [48]. Elements may include: functional ana-
lysis, training communication and/or problem-solving
skills, sobriety sampling, social networking, learning to
refuse substances, increasing alternative reinforcing ac-
tivities, relapse management and medication monitoring.
Treatment is individual but may also be partly group-
wise. Patients receive TAU on a weekly basis by a health
care worker.
Alternatively, some patients in care pathway ‘young’
may receive an intensive family treatment for youngsters
up to 20 years old (and their families), who still live at
home (or intend to go back to live at home again) and
where multiple life domains may be affected (e.g. family,
school, mental health, criminal behavior etc.): Multidi-
mensional Family Therapy (MDFT [49]). Patients of care
pathway ‘addition, care and housing’ receive Function
Assertive Community Treatment (FACT [50]), a multi-
disciplinary, outreaching approach aimed at stabilization,
treatment and recovery.
TAU is supervised by a clinical psychologist or psych-
iatrist. If necessary, treatment may be supplemented
with medical care (such as, but not limited to medica-
tion), individual psychological care or relationship or
family therapy. Incidentally or periodically, additional in-
patient treatment may be necessary. CRA and MDFT
typically lasts 6 months (in some cases CRA may be lim-
ited to 3 or extended to 9 months) while FACT may en-
dure much longer.
‘Time-in-treatment’ before intervention and during
the course of the study as well as main components and
treatment intensity of TAU will be registered. The use of
psychofarmaca, craving reducing (acamprosate, naltrex-
one) or abstinence enforcing medication (disulfuram)
will be monitored.
Eye movement desensitization and reprocessing (EMDR)
Participants allocated to the EMDR + TAU group will
receive a manualized intervention. This set of EMDR
protocols was developed by the principal investigator
and the EMDR International Association (EMDRIA)-
approved consultant involved in this study as a trainer.
It incorporates elements of existing EMDR addiction
protocols [35,37,38], related work [51] and insights on
positive and prospective memory representations [19,20].
Based on pilot treatments, the intervention manual was
fine-tuned before the recruitment phase.
Participants receive a maximum of seven weekly,
90-minute EMDR sessions provided by health care psy-
chologists (who at least completed an EMDRIA-approved
Basic Training program). The EMDR therapists will be
trained in the use of the intervention manual and will be
supervised monthly by the EMDR consultant. All EMDR
sessions are video-recorded for fidelity rating and supervision.
Session one starts with instruction on some rules and
the rationale for EMDR and its use in addiction. Then
the treatment goal (controlled drinking or abstinence) is
established. Subsequently participants are instructed to
imagine their positive treatment goals vividly. After that
both negative associations with long-term abstinence
(if present) and positive memories associated with alcohol
use are targeted with EMDR. At the end a homework diary
is presented and participants are instructed to keep it daily,
between sessions. It helps to register daily craving, alcohol
use, possible adverse and/or positive events and help
participants to prepare for the next session by identify-
ing possible targets. Subsequent sessions focus on memory
representations associated with loss of control, self-
efficacy undermining beliefs, trigger situations, and anti-
cipated relapse. Finally the focus shifts to feeling more
empowered in trigger situations. Therapists are instructed
to keep the duration of sessions as constant as possible,
selecting only the most relevant targets. In some cases,
fewer sessions may be required and provided.
Termination of treatment
Regarding EMDR treatment, completers are defined as
completing five or more of the scheduled seven EMDR
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sessions, allowing for some flexibility on the basis of
clinical need. Those who attend four EMDR sessions or
fewer for any reason comprise a premature termination
of treatment (PTT) group.
Regarding TAU, a similar distinction is made whereby
a completer attended five or more weeks of treatment
(at least one face-to-face contact weekly) between T0
and T1 while those who attend four weeks or less of
TAU fall in the PTT category.
Data collection
Subjects participate in the study for 8 months (from T0
to T3). Patients in both treatment conditions will be
assessed identically (see Table 1). Two instruments are
only used during the inclusion interview: the MINI-Plus
[43] and the MATE 2.1 [44]. At T0, RA1 (blinded to treat-
ment allocation) assesses baseline measurements of all pri-
mary, secondary, tertiary and quaternary variables. At T1
(post treatment), T2 (follow-up after 1 month) and T3
(follow-up after 6 months) all but one (the ‘readiness for
change’ as measured with the RCQ-D [52] is only assessed
at baseline) measurements are repeated by RA1.
For participants in the EMDR + TAU group additional
assessments take place within (pre and post levels of dis-
tress, craving or positive affect of memory representa-
tions on a 11-pt Likert scale) and between (daily diary:
number of drinks, intensity and frequency of craving,
adverse events) sessions. These assessments are an inte-
gral part of the EMDR intervention manual and can
therefore only be used to explore changes during the
course of EMDR within this group. EMDR therapists
also fill in a questionnaire after the last EMDR session
of each participant regarding perceived and experienced
treatment burden credibility and harm, before, during
and after treatment.
RA1 also gathers demographic data: age, sex, social-
economic and marital status, educational level, and eth-
nicity. Participant-report questionnaires (no 3–11 in
Table 1 below [6,52-59]) will be provided digitally using
Perseus web survey software [60]. The alcohol Timeline
Followback interview (TLFB; [61]) is conducted face-to-
face by RA1.
The alcohol Stroop [62] and valence IAT [63] will be
administered using the program Inquisit 3 [64] for com-
puterized assessment.
After each on-site assessment, participants are referred
to a laboratory nearby for collection of blood samples to
determine GGT and CDT [65]. Results are interpreted by
an independent physician from IrisZorg. The results will
be discussed with the participants after the last assessment
by this physician, if relevant. In the case that lab results
merit intervention before the last follow up assessment,
the physician will notify the regular addiction care phys-
ician or general practitioner as soon as possible.
Instruments
Measurements - inclusion
Measurements in the addictions for triage and evaluation
(MATE 2.1 [44]) The MATE is composed of 10 modules
made up of a set of existing psychometrically validated
short instruments from the public domain. In this
study, RA1 only uses parts 1–4 to screen for eligibility
criteria.
Module 1: ‘USE’, is an interview used to determine the
severity of the use of psychoactive substances in the
previous 30 days as well as life-time. Inventarisation of
substances (including nicotine and gambling), the level
of use and typical form or route of application are
reported. Use (in standard units) in the past period and
use on a typical day of use are reported, as well as the
number of years of regular use. The primary problem
substance or behaviour is identified.
Module 2: ‘INDICATIONS PSYCHIATRIC OR
MEDICAL CONSULT’. Medical themes interviewed:
1) use of medication for addiction; 2) use of medication
for other somatic complaints; 3) symptoms that may be
the result of severe physical health problems; 4)
intoxication or (severe) withdrawal symptoms; and
5) pregnancy. Psychological/psychiatrical themes
interviewed: 1) current and recent psychiatric or
psychological treatment; 2) use of medication for
psychiatric reasons; and 3) suicide risk and psychotic
symptoms.
Module 3: ‘ADDICTION TREATMENT HISTORY’.
This part of the interview questions whether and if so
how much previous addiction treatments the
participant has undergone in the past 5 years.
Module 4: ‘DEPENDENCE AND ABUSE’. The
questions are derived from the section Alcohol &
Drugs from the CIDI (Composite International
Diagnostic Interview) 2.1 [66] in accordance with the
diagnostic criteria for substance abuse or dependence
of the DSM-IV-TR [41]. In this study, the questions will
relate to alcohol use since this will be the primary
problem substance.
Mini-international neuropsychiatric interview (MINI-
plus [43,67]) This brief, structured interview allows for
the coding of more than 60 variables, including DSM-
IV-TR disorders (23 axis 1 disorders) and suicide risk at
the time of the interview or at some time in the past.
Psychometric evaluation of the English version of the
MINI (a less detailed version of the MINI-plus) showed
that inter-rater reliability is good while test-retest reli-
ability is satisfactorily, expect for current manic episode.
Most scales possess a satisfactory degree of predictive
power but positive predictive power for lifetime bulimia
nervosa, social phobia and generalized anxiety disorder
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is relative weak [68]. Content validity of simple phobia
and generalized anxiety disorder, when compared to the
CIDI [66], was also low.
The MINI-Plus employs different time frames for vari-
ous disorders: current, past, or lifetime. For screening
purposes, we will only focus on the ‘current’ timeframe.
Measurements – effects on drinking behavior
Alcohol use disorders identification test (AUDIT;
[53,69] The AUDIT is a 10-item, self-report measure
assessing harmful alcohol consumption (items 1 to 3),
drinking behavior (items 4 to 6), adverse reactions to al-
cohol (items 7 to 8), and alcohol-related problems (9 to
10). Scores on items 1 to 8 can range from 0 to 4, while
items 9 and 10 are scored 0, 2, or 4. Higher scores indi-
cate higher risk and range from 0 to 40. Scores between
8 and 12 indicate hazardous or harmful alcohol use,
while scores 13 to 40 indicate likely alcohol dependence
[70,71]. A high reliability, sensitivity, and specificity of
the scale has been reported [53].
The timeframe normally used is that of the previous
year. However, since we want to repeat the AUDIT assess-
ment, this time frame would cause overlap between as-
sessments. Therefore we will use a time-frame of 1 month.
Alcohol timeline followback (TLFB [60]) The Alcohol
TLFB is a drinking assessment method that obtains esti-
mates of daily drinking and has been evaluated with
clinical and non-clinical populations. Using a calendar,
people provide retrospective estimates of their daily
drinking over a specified time period that can vary up to
12 months from the interview date. In this study retro-
spective estimates of the previous month will be used.
Several memory aids can be used to enhance recall (e.g.,
calendar; key dates serve as anchors for reporting drinking;
standard drink conversion). The Alcohol TLFB has been
shown to have good psychometric characteristics with a
variety of drinker groups, and can generate variables that
provide a wide range of information about an individual’s
drinking (e.g., pattern, variability, and magnitude of drink-
ing). The method is recommended for use when relatively
precise estimates of drinking are necessary, especially when
a complete picture of drinking days (i.e., high- and low-risk
days) is needed (evaluating drinking pre-posttreatment).
Although Timeline summary data have been found to be
generally reliable, as with all drinking assessment methods,
exact day-by-day precision cannot be assumed or necessar-
ily expected. Overall, the Alcohol TLFB method provides a
relatively accurate portrayal of drinking, and has both clin-
ical and research utility.
Serum γ-glutamyltransferase (GGT) and carbohydrate-
deficient transferrin (CDT) CDT is currently the most
specific marker of alcohol abuse, and when combined
with GGT using an equation [0.8*ln(GGT) + 1.3*ln
(CDT)] a high sensitivity is reached without loss of spe-
cificity [64]. The Dutch multidisciplinary protocol for al-
cohol problems [72] also states that assessment of CDT
levels, which may be combined with those of GGT, is
suitable to monitor reduction of or abstinence from
(chronic) alcohol use;
Measurements – mediators, moderators and predictors of
treatment outcome
Readiness to change questionnaire (RCQ; [52,73] The
RCQ is an instrument which tries to capture the stage of
change the patient is in, according to the stages of change
model [74]. The RCQ has 12 items which have to be
answered on a 5-point scale. There are three subscales
reflecting pre-contemplation, contemplation and action.
The instrument has a satisfactory internal consistency and,
in most studies, a satisfactory test-retest reliability ([73],
p. 752). The predictive validity of the original instrument is
sufficient: the RCQ predicts changes in drinking behavior
[75]. However, one study found that there was little agree-
ment between self- and interviewer rating of the alcohol
version of the RCQ and between self-report on different
instruments relating to the same concepts [76].
The psychometric quality of the RCQ-D (translated by
[73]) seems comparable to the original. Some negative
formulated questions were transformed into positive
formulations. Although the underlying transtheoretical
model has been criticized [77], the questions in itself
can provide insight into the motivation for change and
drinking related appraisals at the moment of assess-
ment. The instrument can assist in distinguishing those
patients who are ready to change their drinking behav-
ior and those who are probably in need of further mo-
tivational counseling [73].
Penn alcohol craving scale (PACS; [57]) The PACS is
a measure of weekly craving. The PACS was selected be-
cause prior research has demonstrated the PACS to have
greater predictive value for treatment outcomes com-
pared to the Obsessive–Compulsive Drinking Scale or
the Alcohol Urge Questionnaire [78]. The PACS consists of
five items each scored 0–6 in increasing severity of craving.
The PACS has excellent internal consistency [57]. Pre-
dictive, construct, discriminant validity was demonstrated.
The PACS is a reliable and valid measure of alcohol crav-
ing and can predict which individuals are at risk for subse-
quent relapse. Although the instrument has not been
translated and validated in the Netherlands, we believe the
brevity and psychometric qualities of the original instru-
ment makes it suitable for the current study. A Dutch ver-
sion (translated by two independent researchers and
discussed after which consensus was reached on a final
translation) was used here.
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Desire thinking questionnaire (DTQ; [6]) The DTQ is
based on the elaborated intrusion theory of desire [79].
Items are scored on a 4-point Likert-type scale (“Almost
never”, “Sometimes”, “Often” or “Almost always”). Al-
though the DTQ uses no timeframe, here we focus on
the previous month in order to make sure there is no
overlap in timeframe between subsequent assessments.
Differentiated in a total score (10 items × 1–4 points
(range 10–40 points)) and subscores for the factors Ver-
bal Perseveration and Imaginal Prefiguration (5 items ×
1–4 points (range 5–20 points)). The first factor relates
to ‘repetitive self-talk regarding the need to achieve the
desired target and self-motivated statements’. The latter
relates to the ‘construction of mental images of the de-
sired target or of its context of consumption.
Psychometric evaluation demonstrated an acceptable
level of internal consistency [6]. A moderate correlation
between desire thinking, craving and rumination indi-
cated that these concepts can be considered as divergent
constructs. Test-retest reliability for both factors (.66
and .56) and total score (.59) was acceptable.
Predictive validity was determined in a sample of alco-
hol abusers seeking treatment from a variety of alcohol
services (n = 78). Both DTQ factors correlated positively
and significantly with craving, but only ‘Verbal Persever-
ation’ correlated positively and significantly with the
level of alcohol use (but did not predict level of alcohol
use in addition to the variance explained by craving).
DTQ factors predicted craving independently of level of
alcohol use.
Positive and negative affect schedule – short form
(PANAS-SF; [58] This 10-item instrument is a trans-
lated, Dutch version of the International PANAS-SF
(I-PANAS-SF; translated from English by comparing it to
the validated 20-item Dutch version of the PANAS [80], it-
self a translation of the original English version of the
PANAS [81]).
Each item refers to a mood state and participants rate
the extent to which each mood state describes how they
feel at the moment of testing on a scale ranging from 1
(never) to 5 (always). It captures two dimensions of mood:
positive and negative affect. Low positive affect (PA) corre-
sponds to lethargy and sadness, whereas high PA reflects
high energy, concentration and pleasurable mood states.
Negative affect (NA) refers to distress and unpleasurable
mood states, with low NA reflecting a state of calmness
and serenity. One study demonstrated adequate reliability
of the PA and NA subscales of the I-PANAS-SF [81]. The
instrument compares well with the full 20-item original of
both correlating with the original full form and tem-
poral stability. Although the validity of the instrument
in relation to stress and psychopathology needs to be
determined, the brevity and straightforwardness of the
instrument make it useful for repeated measurements,
especially in the multiple baseline study. In addition,
both PA and NA seem to play a role in conferring risk
and maintaining substance use [11]. Most short affect
measures only capture aspects of NA.
Perseverative thinking questionnaire (PTQ; [59] The
15-item PTQ was recently developed to provide a
content-independent measure of repetitive negative
thinking (RNT). Preliminary validation supported lower
order factors representing 1) the core characteristics of
RNT (repetitiveness, intrusiveness and difficulties with
disengagement), 2) perceived unproductiveness of RNT
and 3) RNT capturing mental capacity. The PTQ shows
good reliability and validity and recently a Dutch ver-
sion was validated [82]. Each item is rated on a 5-point
scale ranging from 0 (never) to 4 (almost always). No
timeframe is used.
Alcohol stroop (derived from classic Stroop test
[62,83]) A modified, computerized Stroop color-naming
task with alcohol-related words (alcoholic drinks) as well
as neutral (non-alcoholic drinks) words is used. The
stimulus words are presented on a 17 inch laptop (using
Inquisit 3 desktop software) in 4 different colors (yellow,
red, green and blue). Participants view 3 screens (each
representing a matrix of 5 columns and 8 rows, equaling
a set of 40 stimuli) with different stimulus sets in a ran-
domized, counterbalanced (between subjects) fashion: a)
4 × 10 alcohol-related words (beer, wodka, wine, rum,
port, cognac, whiskey, gin, liqueur and jenever), b) 4 ×
10 neutral words (7-up, orange juice, apple juice, cola,
Fanta, cassis, water, lemonade, spa, Pepsi) or c) 40 non-
words (series of colored XXX). This amounts to 1 trial
per set. Each of the ten selected words is presented four
times per set in a fixed order. The order of the colors is
fixed as well. The same word or ink color does not occur
more than twice in a row. All stimuli appear in lower-
case Arial font (regular). The font size is 14. The pro-
jected stimuli appeared on the computer screen as color
words presented against a black background.
This task allows assessment of interference (on atten-
tional processing) due to alcohol cues. Shorter response
latencies on alcohol-related rather than neutral words
are assumed to indicate a stronger alcohol-related bias.
In the version used here, participants are required to re-
spond vocally to stimuli. Participants only name the ink
color, reading as fast as possible from left to right and
from top to bottom. Timing was done manually: directly
after the last ink-color is named, the experimenter clicks
the mouse, recording the total time per set. Number of
errors are recorded manually by the experimenter. Both
the alcohol-related and neutral scores are corrected by
subtracting the non-word score.
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Implicit association task (IAT; [84] Here the valence
version [63] is used (derived from the Inquisit task li-
brary [85]). This IAT contains two sets of two word cat-
egories. The target words consist of alcoholic drinks
(“beer”, “wine, “port, “whisky”, “vodka” and “rum”) or
sodas (“Coke”, “Cassis”, “Sinas”, “Spa”, “tonic”, and
“juice”). The attribute set consists of positive (“sociable”,
“good”, “pleasant”, “nice”, “enjoyable” and “sympathetic”)
and negative words (“antisocial”, “bad”, “unpleasant”,
“stupid”, “obnoxious” and “tedious”). The Dutch words
were matched for prevalence and number of syllables
[63]. The stimulus words are presented on a 17 inch lap-
top (using Inquisit 3 desktop software).
The IAT has nine phases that come in one of two or-
ders. Every phase consists of one practice block and ei-
ther one or two measurement blocks. Each block
consists of 48 randomly selected words. Attribute words
(positive or negative) are presented in black (fontsize 14)
in the middle of the screen. Feedback appears in red
(fontsize 16) below the stimuli words. In case of a wrong
response, the word “ERROR” appears on the screen.
After responses that are too fast (<150 ms) or too slow
(>3 s), feedback follows (“TOO FAST” or “TOO
SLOW”) with a warning beep. The category word or
words (alcohol or soda words) are presented at the top
of the screen, on the left or the right side, depending on
the required response (as in Greenwald et al., 1998). The
interstimulus interval is 250 ms.
Self-efficacy list for drug users (SELD; [54]) The 19-
item SELD measures situational abstinence self-efficacy.
The authors state that self-efficacy should not be consid-
ered a stable quality of a person, but depends on the
situation in which the person finds oneself. Three corre-
lated dimensions were found: environmental factors,
negative mood and positive mood. SELD scores corre-
lated as expected with severity of drug use. Although it
is a reliable and valid instrument to measure self-efficacy
in substance users, test-retest reliability and predictive
validity remains to be established.
Measurements – effects on quality of life
EuroQol-5D (EQ-5D; [55] The EQ-5D is a short (14
VAS scales (0–100)) generic health-related quality of life
(HRQOL) patient-report questionnaire which assesses 5
health dimensions (mobility, self-care, usual activities,
pain/discomfort and anxiety/depression). Responses in
each dimension are divided into three ordinal levels
coded: no, moderate or extreme problems. Test-retest
reliability and convergent validity are satisfactory in dif-
ferent populations [86,87] but the EQ-5D may show a
moderate ceiling effect, thus indices seem less responsive
for detecting meaningful clinical differences in alcohol-
dependent patients compared to other instruments [88].
Community reinforcement approach happiness scale
(CRA-HS; [48]) The CRA-HS is a multidimensional in-
strument that examines a wide variety of life areas on
10-point Likert scales. It forms the foundation of a CRA
treatment plan and is used to determine individuals’
current “happiness” in terms of satisfaction or quality of
life. It casts light on the severity of problems for each area
and subsequently can be used to evaluate treatment out-
come by repeatedly assessing changes that occur during
treatment. The instrument encompasses life areas such as
drinking (or illegal drug use), household, job/education,
money management, social life, personal habits, romantic
relation, family relationships, legal issues, emotional life,
communication, health and general happiness. Preliminary
results show that the instrument has overall satisfactory
internal consistency and sensitivity to changes over a
follow-up period of a month [56]. In addition, scores cor-
related with the level of rewarding activities.
Measurements – safety, acceptability and feasibility of
treatment
All regular care providers, EMDR therapists involved in
the study, treatment supervisors and physicians have been
instructed to report adverse events (AE) and serious ad-
verse events (SAE) which may arise during treatment. At
T1 all regular therapists are e-mailed with questions about
possible SAE that may have gone unreported between T0
and T1. In addition, all participants are questioned about
possible AE and SAE at all time-points. Finally, partici-
pants in the EMDR +TAU group keep a daily diary during
EMDR treatment in which they are instructed to report
(S)AE.
At each time-point participants answer questions
about opinions and expectations regarding the treatment
(be it TAU or EMDR + TAU) they received, the credibil-
ity and burden of treatment. In addition, at the end
(completed or not) of each EMDR treatment, the EMDR
therapist is required to answer some exit-questions re-
garding the feasibility of the treatment for this particular
participant. More generally, before the first and after the
last EMDR treatment in the data collection phase EMDR
therapists fill in a questionnaire about their opinions
and expectations regarding the EMDR training and
supervision, the credibility and burden of treatment.
Fidelity checks
EMDR therapists receive one full and two half-days of
training in the EMDR treatment protocol. All EMDR ther-
apists will be supervised by an EMDR consultant to guide
optimal application of the treatment protocol. Monthly,
two-hour group supervision supports the EMDR therapist
for the whole duration of the data collection phase. Be-
tween supervision sessions, the consultant is available for
consultation by email. All EMDR treatment sessions will
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be videotaped. A random selection will be rated for treat-
ment fidelity by several independent raters with EMDRIA
approved basic training. Deviations from the protocol will
be reported to the consultant and EMDR therapist.
Since participants are randomized and TAU is there-
fore assumed equal in both groups, no fidelity checks
are done regarding TAU.
Analyses
All analyses will be executed using SPSS. Summary ta-
bles will be provided for all baseline, end of treatment
and follow-up variables. Data will be summarised using
frequency tables (with confidence intervals when applic-
able), and descriptive statistics (mean, median, interquar-
tile range, number and percentages of participants and
two-sided, 95% confidence intervals when appropriate).
Changes in the number of heavy drinking days in the
past 30 days will be used to analyze the efficacy and ef-
fectiveness of EMDR. Since this primary outcome vari-
able is continuous, a repeated measures ANOVA will be
carried out with 2 group (EMDR + TAU versus TAU)
and 4 time (pre-, post-treatment, 1 and 6 month follow-
up) factors. Randomization stratum will be used as a co-
variate. Effect sizes will be calculated.
All allocated participants will be included in the primary
analysis (intention-to-treat, ITT). Since an ideal ITT re-
quires a complete set of data [89], multiple imputation (or
a similar strategy) will be used for missing data, if possible.
In addition a per-protocol (PP or completers) analysis will
be done. ITTanalyses will provide insight into the effective-
ness of the treatment in real life whereas PP analysis gives
insight into the efficacy or the ability for the treatment to
reach its intended effect under ideal circumstances.
Repeated measures of continuous secondary variables
such as time to first alcohol consumption, number of
total drinks consumed and average drinks per occasion
in the past 30 days, severity of the dependence, level of
rumination, negative affect, desire thinking, craving, cop-
ing self-efficacy, quality of life, biomarkers will be ana-
lyzed by carrying out a repeated measures ANOVA with
2 group (EMDR + TAU versus TAU) and 3 (post treat-
ment versus 1 versus 6 month follow-up: time to first
drink variable derived from TLFB data) or 4 time (pre-
versus post-treatment versus 1 versus 6 month follow-
up: all other data) factors.
Distribution of premature treatment termination
(PTT), a categorical variable, will be analysed using chi-
square tests. A range of baseline clinical characteristics
potentially associated with subsequent PTT will be ex-
amined. A logistic regression analysis will be conducted
to examine the relative contribution of key variables to
PTT status. A Kaplan–Meier survival curve will be used
to illustrate the distribution of PTT prior to the comple-
tion threshold at session 5.
Group equivalence will be analyzed using independent
t-tests to compare the experimental with the control
group on continuous baseline or pretreatment measures
of severity and duration of alcohol dependence, motiv-
ation to change, coping self-efficacy, quality of life,
craving, desire thinking, rumination, negative affect
and biomarker levels of GGT and CDT. Group equiva-
lence of categorical variables, such as level of educa-
tion, history of other substance use, specific contents
of TAU use of anti-craving, abstinence enforcing or
other psychoactive medication during the study treat-
ment phase and co morbidity will be analyzed using
chi-square tests.
Variables such as use of anti-craving, abstinence en-
forcing or other psychoactive medication, time-in-
treatment, craving, rumination, negative affect and
desire thinking at T0, may be used as covariates after
determining correlations with other primary and sec-
ondary outcome measures.
Discussion
This RCT aims to extend previous findings [15] by in-
cluding a larger number of participants, using reaction
time tasks and bloodsamples in addition to participant-
report questionnaires and scales, excludes the principal
investigator from treatment and data-collection and uses
an outpatient instead of an inpatient setting. A strength
of the study is that it is a multi-site trial, enhancing the
internal and external validity of the interventions. An-
other strength is that the exclusion criteria are limited,
enhancing the generalizability of findings. In addition, by
identifying mediators, moderators and predictors of
treatment outcome theoretical models of relapse may be
expanded.
The main goal of the study is to determine whether
EMDR, when added to TAU, reduces drinking behavior
and relapse rates further than TAU only. Even a rela-
tive small effect size may be relevant, when achieved
with a limited dose of EMDR. In addition, EMDR may
provide an important adjunct to current treatment op-
tions for patients suffering from craving, negative
affect and rumination. In both cases the quality of life
is expected to improve.
Finally, the study is aimed at establishing whether the
application of EMDR aimed at addiction is feasible and
safe in this patient population, even when patients still
use substances. Clinicians may be hesitant to use EMDR
in this population because they fear triggering craving
and subsequent relapse.
Trial status
Currently recruiting participants and started with
data collection.
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